
Keywords: prostatic neoplasms; castration-resistant; subcutaneous fat; prognosis; tomography; x-ray computed; mortality; ADT; androgen deprivation therapy; ARAT; androgen receptor axis targeted; BMI; body mass index; CCI; Charlson Comorbidity Index; CRPC; castratio